Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
- PMID: 17616706
- DOI: 10.1158/0008-5472.CAN-06-3280
Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
Abstract
We have previously shown preferential tumor-homing and therapeutic efficacy of adoptively transferred type 1 CTL (Tc1) when compared with type 2 CTL (Tc2) in mice bearing intracranial ovalbumin-transfected melanoma (M05). Further characterizing the expression of a panel of homing receptors on Tc1 and Tc2 cells, we found that very late antigen (VLA)-4 (a heterodimer of CD49d and CD29), but none of other receptors evaluated, was expressed at significantly higher levels on Tc1 cells than on Tc2 cells. Although CD49d (alpha(4) integrin) can form heterodimers with both beta(1) (CD29) and beta(7) integrins, alpha(4)beta(7) complexes were not expressed by either Tc1 or Tc2 cells, suggesting that CD49d is solely expressed in VLA-4 complexes. VLA-4 expression on Tc2 cells was down-regulated in an interleukin (IL)-4 dose-dependent manner but not by other type 2 cytokines, such as IL-10 and IL-13, suggesting that IL-4 uniquely down-regulates VLA-4 expression on these cells. In accordance with the differential expression of VLA-4 on Tc1 versus Tc2 cells, Tc1 cells alone were competent to adhere to plate-bound VCAM-1-Ig fusion protein. Finally, the efficient trafficking of Tc1 cells into intracranial M05 lesions in vivo was efficiently blocked by administration of monoclonal antibodies against CD49d or VCAM-1 or small interfering RNA-mediated silencing of CD49d on Tc1 cells. Collectively, these data support the critical role of VLA-4 in the effective intracranial tumor homing of adoptive-transferred, antigen-specific Tc1 cells and suggest that more effective vaccine and/or ex vivo T-cell activation regimens may be developed by promoting the generation of VLA-4(+) antitumor Tc1 cells.
Similar articles
-
IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.Eur J Immunol. 2008 Oct;38(10):2865-73. doi: 10.1002/eji.200838334. Eur J Immunol. 2008. PMID: 18958887 Free PMC article.
-
Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.Cancer Res. 2006 Apr 15;66(8):4478-87. doi: 10.1158/0008-5472.CAN-05-3825. Cancer Res. 2006. PMID: 16618775
-
Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.J Immunol. 1999 Jun 1;162(11):6671-80. J Immunol. 1999. PMID: 10352285
-
Brain tumor immunotherapy with type-1 polarizing strategies.Ann N Y Acad Sci. 2009 Sep;1174:18-23. doi: 10.1111/j.1749-6632.2009.04932.x. Ann N Y Acad Sci. 2009. PMID: 19769732 Review.
-
VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.Int J Mol Sci. 2020 Mar 23;21(6):2206. doi: 10.3390/ijms21062206. Int J Mol Sci. 2020. PMID: 32210016 Free PMC article. Review.
Cited by
-
Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity.Nat Commun. 2015 May 13;6:7114. doi: 10.1038/ncomms8114. Nat Commun. 2015. PMID: 25968334 Free PMC article.
-
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.Clin Cancer Res. 2019 Jul 15;25(14):4202-4210. doi: 10.1158/1078-0432.CCR-18-1627. Epub 2019 Feb 25. Clin Cancer Res. 2019. PMID: 30804019 Free PMC article. Review.
-
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.Cancer Immunol Immunother. 2008 Sep;57(9):1279-89. doi: 10.1007/s00262-008-0461-1. Epub 2008 Feb 6. Cancer Immunol Immunother. 2008. PMID: 18253732 Free PMC article.
-
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.Front Pediatr. 2013 Jun 10;1:12. doi: 10.3389/fped.2013.00012. Front Pediatr. 2013. PMID: 24400258 Free PMC article. Review.
-
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.J Immunother Cancer. 2013 Dec 16;1:21. doi: 10.1186/2051-1426-1-21. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829757 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous